Loading...
OTCM
NBIO
Market cap34kUSD
Jul 09, Last price  
0.00USD
1D
0.00%
1Q
-33.33%
Jan 2017
-99.92%
IPO
-99.67%
Name

Nascent Biotech Inc

Chart & Performance

D1W1MN
OTCM:NBIO chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
38.93%
Rev. gr., 5y
%
Revenues
0k
00003,000,000000750,0001,000,00000
Net income
-2m
L-25.46%
-689,000-1,918,000-2,152,000-4,149,0001,137,000-2,221,000-1,369,000-4,004,153-959,000-470,000-2,801,000-2,088,000
CFO
-1m
L-33.64%
-85,851-129,529-473,297-170,421-768,844-1,224,381-711,808-554,325-986,784413,479-1,787,228-1,186,066

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nascent Biotech, Inc., a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma. This drug also targets numerous epithelial cancers, including those affecting the lung, breast, colon, brain, and pancreas. Additionally, the company is advancing MultiPharm, its proprietary technology platform, which holds promise for applications in cancer therapy, diabetes, autoimmune disorders, and transplantation. The company's headquarters are situated in Vero Beach, Florida.
IPO date
Jun 06, 2012
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT